bioAffinity receives Nasdaq delisting notice for bid price non-compliance; plans appeal

bioAffinity Technologies, Inc.

Received Staff Determination on July 30, 2026, for bid price below $1.00 for 30 consecutive business days.
Not eligible for 180-day compliance period due to reverse stock split within prior year (1-for-30 on Sept 19, 2025).
Intends to appeal on August 6, 2026, which will stay delisting pending panel decision.
No assurance of regaining compliance or continued listing on Nasdaq Capital Market.

Featured in Daily 8-K Digest

Selected #5 for 2026-07-31. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.